Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-653 CNS Pharmacodynamics in Healthy Volunteers
NCT03792672Phase 1Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Feb 2019
- Primary completion
- May 2019
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of osavampator in major depressive disorder (MDD) (6 arms), sponsored by Neurocrine Biosciences. Primary endpoints: Change From Baseline in Peak-to-Peak Amplitude of Motor-evoked Potential (MEP) and Change From Baseline in Resting Motor Threshold (rMT). Started Feb 2019; status: completed.
02
Drugs
osavampator
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03792672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03792672.